Bashier Alaaeldin, Khalifa Azza Abdulaziz, Rashid Fauzia, Abdelgadir Elamin Ibrahim, Al Qaysi Amina Adil, Ali Razan, Eltinay Ahmed, Nafach Jalal, Alsayyah Fatima, Alawadi Fatheya
Endocrine Department, Dubai Hospital, Dubai, United Arab Emirates.
Internal Medicine Residency Program, Dubai Hospital, Dubai, United Arab Emirates.
J Clin Med Res. 2017 Jun;9(6):499-507. doi: 10.14740/jocmr2976w. Epub 2017 Apr 26.
SGLT2 inhibitors are a new class of drugs that act by inhibiting glucose reabsorption in the proximal renal tubules. Many trials have demonstrated their effectiveness in reducing glycated hemoglobin (HbA1c) and weight, but they have never been examined in Arab or Emirati populations.
We assessed the efficacy of SGLT2 inhibitors in reducing HbA1c and weight in our population and specifically in an Emirati cohort. We also assessed the effect on fasting blood glucose, blood pressure, lipid profile, serum creatinine, and side effects.
The total number of patients was 307. The baseline HbA1c in the Emirati cohort was 8.9±1.7%, which dropped significantly to 8±1.5% at 6 months (P = 0.0001). At 1 year, the mean HbA1c was 8±1.4%, which was significantly different from baseline (P = 0.0001). However, the change in mean HbA1c from 6 months (8±1.5%) to 1 year (8±1.4%) was not statistically significant (P = 0.88). A similar highly significant change was observed when comparing weights at baseline and 6 months in the Emirati population (85.7 ± 17.8 kg vs. 84 ± 17.2 kg, P = 0.0001). Total cholesterol dropped significantly at 6 months (P = 0.008), as did low-density lipoprotein (LDL) (P = 0.005).
The use of SGLT2 inhibitors is associated with significant reductions in HbA1c and weight. Unlike all previous trials, the inhibitors significantly reduced total cholesterol and LDL. Larger trials are needed to reassess their effects on lipid parameters.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一类新型药物，其作用机制是抑制近端肾小管对葡萄糖的重吸收。许多试验已证明其在降低糖化血红蛋白（HbA1c）和体重方面的有效性，但从未在阿拉伯或阿联酋人群中进行过研究。
我们评估了SGLT2抑制剂在我们的人群中，特别是在阿联酋队列中降低HbA1c和体重的疗效。我们还评估了其对空腹血糖、血压、血脂谱、血清肌酐及副作用的影响。
患者总数为307例。阿联酋队列的基线HbA1c为8.9±1.7%，在6个月时显著降至8±1.5%（P = 0.0001）。1年时，平均HbA1c为8±1.4%，与基线相比有显著差异（P = 0.0001）。然而，平均HbA1c从6个月时的（8±1.5%）到1年时的（8±1.4%）的变化无统计学意义（P = 0.88）。在比较阿联酋人群基线和6个月时的体重时，观察到了类似的高度显著变化（85.7±17.8千克对84±17.2千克，P = 0.0001）。总胆固醇在6个月时显著下降（P = 0.008），低密度脂蛋白（LDL）也是如此（P = 0.005）。
使用SGLT2抑制剂与HbA1c和体重的显著降低有关。与以往所有试验不同的是，这些抑制剂显著降低了总胆固醇和LDL。需要进行更大规模的试验来重新评估它们对血脂参数的影响。
